Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Strontium Ranelate

NICE TA: 160,161
Indication: Primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160 & 161)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No


The EMA has considered that strontium ranelate should only be used by people for whom there are no other treatments for osteoporosis. The cardiovascular risks identified with strontium ranelate may be sufficiently reduced in this population by restricting its use to people without cardiovascular contraindications. Please see link to the Drug Safety Update on the MHRA website for further information (in supporting documents below)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG